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Evaluation of 1025 fetal deaths: proposed diagnostic workup
Fleurisca J. Korteweg, MD, PhD; Jan Jaap H. M. Erwich, MD, PhD; Albertus Timmer, MD, PhD;
Jan van der Meer, MD, PhD; Joke M. Ravisé; Nic J. G. M. Veeger, PhD; Jozien P. Holm, MD, PhDOBJECTIVE: We sought to evaluate the contribution of different diag-
nostic tests for determining cause of fetal death. Our goal was to pro-
pose a workup guideline.
STUDY DESIGN: In a multicenter prospective cohort study from 2002
hrough 2008, for 1025 couples with fetal death20 weeks’ gestation, an
xtensive nonselective diagnostic workup was performed. A panel classi-
ed cause and determined contribution of diagnostics for allocating cause.
RESULTS: A Kleihauer-Betke, autopsy, placental examination, and cy-
togenetic analysis were abnormal in 11.9% (95% confidence interval
[CI], 9.8–14.2), 51.5% (95% CI, 47.4–55.2), 89.2% (95% CI, 87.2–
2012;206:53.e1-12.
See related editorial, page 191.1), and 11.9% (95% CI, 8.7–15.7), respectively. The most valuable
tests for determination of cause were placental examination (95.7%;
95% CI, 94.2–96.8), autopsy (72.6%; 95% CI, 69.2–75.9), and cyto-
genetic analysis (29.0%; 95% CI, 24.4–34.0).
CONCLUSION: Autopsy, placental examination, cytogenetic analysis,
and testing for fetal maternal hemorrhage are basic tests for workup
after fetal death. Based on the results of these tests or on specific clini-
cal characteristics, further sequential testing is indicated.
Key words: antepartum stillbirth, cause of death, intrauterine fetal












oFetal death is a devastating experiencefor parents and caregivers. A complex
chain of events often precedes the fetal
death.Health care workers are responsible
for providing support to families and for
investigating thecauseofdeath.This infor-
mation can give insight intowhy death oc-
curred, which will aid parents in the
mourning process. Furthermore, it will be
of value in determining recurrence risk,
counselingandprevention for futurepreg-
nancies, and audit of the care provided,
and it enables comparison of health care.1
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ported as unexplained inup to two thirds
of stillbirths.2,3 Using a systematic and
well-defined approach to evaluate the
cause of death reduces this percentage.4
However, the optimal workup after fetal
death has not yet been established and
local protocols differ and are often ex-
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ontentsJANUARY 2012 Ameriensure an acceptable chance of determi-
nation of the cause of fetal death.
Several reviews on theworkup after fe-
tal death have been published,3,5,6 how-
ver a prospective, systematic evaluation
f a large cohort of fetal deaths has not
et been performed. Therefore we pro-
pectively analyzed all diagnostic tests of
n extensive protocol in which the con-
ribution of each test was evaluated for
etermining the cause of fetal death ac-
ording to the Tulip classification.7 Our
oal was to propose a guideline for an
ptimalworkup after fetal death in terms
f a high percentage of explained fetal
eaths in combination with a minimum
f testing.
MATERIALS AND METHODS
In 2002, we initiated the prospective intra-
uterine fetal death (IUFD) cohort study in
50 Dutch secondary and tertiary referral
hospitals. Inclusion criteria were singleton
IUFD diagnosed antepartum 20 weeks’
gestation. Pregnancy terminations and in-
trapartum deaths were excluded. The
study was approved by the review boards
of all hospitals and informed consent was
obtained from all participants.
Diagnostic protocol
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Research Obstetrics www.AJOG.orgery. Before the study started we exam-
ined local protocols of participating
hospitals regarding diagnostics after
IUFD. Subsequently the study protocol
was based on these local protocols. Diag-
nostic tests were included in the study
protocol if 70% of hospitals performed
these tests after IUFD. For the study all
participating hospitals followed the
study protocol (Figure 1) and these tests
were offered to all women with an IUFD
so that each couple with IUFDwasman-
aged the same way.
Maternal and fetal blood test results
were compared to local laboratory refer-
ence values and if greater, were consid-
ered abnormal. Maternal and fetal viral
serology and microbiological cultures
were positive if respectively immuno-
globulin levels or culture colonies ex-
ceeded the reference values in the local
laboratory.
Maternal plasma levels collected on
induction of labor of antithrombin, pro-
tein C activity, total and free protein S
antigen, and Von Willebrand factor
(VWF) were measured and the throm-
bophilias factor V Leiden, prothrombin
G20210A mutation (PTG20210A), and
lupus anticoagulant were determined in
the central laboratory.8 Presence of ma-
ernal anticardiolipin antibodies and a
andom maternal plasma homocysteine
abnormal 18.5 mol/L)9 were tested
in local laboratories.
Autopsy and placental examination
were performed by surgical and perinatal
pathologists in participating hospitals. We
urged pathologists to follow the pathology
study protocol based on the guidelines of
the Royal College of Obstetricians and
Gynecologists, the Royal College of Pa-
thologists, and the College of American
Pathologists.7 Cytogenetic evaluation was
performed ingenetic centers10 and radiog-
raphy and magnetic resonance imaging
(MRI) by local radiologists.
Adjudication of cause of death
After individual classification of the
cause,mechanism, origin ofmechanism,
and determination of contributing fac-
tors of fetal death according to the Tulip
classification7 by an experienced multi-
isciplinary panel (consisting of 2 obste-
ricians, an obstetric resident, a perinatal
53.e2 American Journal of Obstetrics& Gynecologathologist and, if needed, expertise by
neonatologist, geneticist, or microbi-
logist), consensus was reached after
iscussion. The cause was defined as
he initial, demonstrable pathophysiologi-
al entity initiating the chain of events that
ad irreversibly led to death. Contributing
actors such as smoking and obesity were
lso identified. In addition, comorbidity
as noted such as: hypertension-related
isease during pregnancy including
hronic hypertension, pregnancy-induced
ypertension, preeclampsia, HELLP syn-
rome, and superimposed conditions.11
Diabetes-related disease during pregnancy
included types 1 and 2 diabetes mellitus
and gestational diabetes with or without
medication.12
Value of diagnostics
Contribution of each diagnostic test for
determination of cause of death accord-
ing to the Tulip classification was evalu-
ated by the samemultidisciplinary panel
first individually and secondly during
the panel sessions. Diagnostics were ad-
judicated valuable if “establishing cause
of death” (an abnormal result of a diag-
nostic test established a cause) or “ex-
cluding cause of death” (a result ex-
cluded a cause of death when there was a
suspected cause of death based on clinical
findings or review of the medical history,
current pregnancy, or antenatal investiga-
tions). We also registered if a test was
“missing for determination of cause of
death” (if there was a suspected cause, the
test exploring that cause was missing).
Statistics
Categorical variables were expressed as
counts and percentages, and continuous
data as means with SD or median and
ranges, with exact 95% confidence inter-
vals (CIs) given when appropriate. Dif-
ferences between groups were evaluated
by the Fisher exact test or 2 test for cat-
gorical data. A 2-tailed P value  .05
as considered to indicate statistical sig-
ificance. Statistical analyses were per-
ormed using software (SAS, version 9.1;
AS Institute Inc, Cary, NC).
RESULTS
From 2002 through 2008 a total of 1164
couples and their fetal deaths were in- o
y JANUARY 2012cluded, of which 1025 were studied (Fig-
ure 1). Investigation into inclusion rates
by comparison of death registration
yearbooks from participating hospitals
yielded an average inclusion of 75%of all
IUFDs eligible for the study. Reasons for
not including IUFDs were: denied in-
formed consent, a language barrier, lo-
gistic problems, and the doctor’s reluc-
tance to include women because of an
already “known” cause of IUFD at birth.
This involveddeathswithplacental abrup-
tion, known chromosomal abnormalities,
andmajor congenital anomalies,which re-
sulted in an underrepresentation of such
deaths in our cohort.
Median age of mothers was 30 years
(range, 17–51 years) and median gesta-
tional age at determination of IUFD was
32weeks and 0 days (range, 20weeks and
0 days–42 weeks and 4 days). The distri-
bution of maternal ethnic origin was
87.1% Caucasian, 4.6% African, 3.8%
Eastern, and 4.5% other. Of these moth-
ers 52.7%were nulliparous.Median fetal
weight was 1528 g (range, 12–5410 g). Of
these babies 37.2% were small for gesta-
tional age (10th growth percentile)
and 10.1% large for gestational age
(90th growth percentile) according to
Dutch Kloosterman13 growth charts.
Diagnostic protocol
How often a test of the study protocol
was performed varied from 98.7% for
placental examination to 3.2% for expert
external fetal examination (Figure 1).
The results of various abnormal maternal
blood tests and the number of women
tested are presented in Table 1. Of the
women with increased glycated hemoglo-
bin (HbA1c) (7.9%), 61.8% were not
known to have diabetes-related disease.
Macrosomia and obesity, known risk fac-
tors for diabetes,14 weremore prevalent in
his group compared to the group with
ormal HbA1c. Fetal blood tests derived
rom the umbilical cord were only per-
ormed in 10.5%mainly due to the impos-
ibility of drawing (enough) blood after
irth.
We recently published on the contri-
ution of coagulation tests.8 As shown in
able 1, in women with IUFD we more
ften observed decreased plasma levels
f antithrombin (17.1%) and protein C
www.AJOG.org Obstetrics ResearchFIGURE 1






















Total IUFD included: 1164 
Informed consent withdrawn: 14
Case record form incomplete due to 
majority of test results missing: 65 
Did not meet inclusion criteria: 60 
Total IUFD studied: 1025
How often a diagnostic test was performed in 1025 fetal deaths   
Prior to delivery after determination of IUFD 
Mother 
 Blood tests: 67.6-98.6% of individual tests performed 
Blood type, Rhesus factor, Thrombocytes, Uric Acid, Urea, Creatinine, Aspartate, Alanine, Lactate 
dehydrogenase (LDH), Bilirubin, Gamma-glutamyltransferase, C-reactive protein, Thyroid-Stimulating 
Hormone, Free thyroxine (T4), random plasma glucose, glycated hemoglobin (HbA1c), Kleihauer-Betke, 
Hemoglobin electrophoresis, Anti-nuclear Antibodies, Antibody screening, HIV, random 
Homocysteine, Anticardiolipin antibodies 
 Viral serology: 79.1-94.0% of individual tests performed 
Toxoplasmosis, Rubella, Cytomegalovirus, Herpes simplex virus, Parvovirus B19, Syphilis, Hepatitis B-
surface-antigen 
 Coagulation tests: 81.4-93.7% of individual tests performed 
plasma levels of Antithrombin, Protein C, total and free Protein S, von Willebrand factor; inherited 
thrombophilias Factor V Leiden, Prothrombin G20210A mutation and lupus anticoagulant 
 Vaginal-rectal swab: 83.2% 
Fetus 




 Blood tests from umbilical cord: 10.5% 
Blood type, Rhesus factor, Hemoglobin, LDH, Bilirubin, Reticulocytes, Creatine phosphokinase 
 Viral serology: 3.6-4.5% of individual testsperformed 
Toxoplasmosis, Rubella, Cytomegalovirus, Herpes simplex virus, Parvovirus B19, Syphilis 
 Ear throat swab: 72.1% 
 Autopsy: 68.8%, external fetal examination by expert if no consent for autopsy: 3.2% 
 Cytogenetic analysis: 42.1%; tissue testing of the fetus (fetal blood, fascia lata, pericard, cartilage, or skin), 
umbilical cord or placenta  
 MRI: 6.0% 
 Radiography: 39.9%   
Placenta 
 Placental swab between the membranes: 59.7% 
 Pathological examination including histopathology: 98.7% 
Inclusion criteria 
Singleton IUFD diagnosed antepartum (heart beat ceased before labor)  20 weeks of gestation 
IUFD, intrauterine fetal death.
































Research Obstetrics www.AJOG.orgactivity (4.2%), and increased levels of
VWF (14.3%), compared to healthy preg-
nant women (in which 2.5% and 97.5%
were the cutoff points for normal ranges).
Overall, inherited thrombophilias in
mothers with IUFDwere not more preva-
lent than in the normal population. This
was also concluded for hyperhomocys-
teinemiaorpresenceof anticardiolipin an-
tibodies.Of the 40womenunfamiliarwith
the antiphospholipid syndrome before the
index pregnancy with either lupus antico-
agulant and/or anticardiolipin antibodies
in this study, the cause of death in 12
IUFDs was placental bed pathology with
origin of mechanism infarction, while 23
had other causes of death and 5 an un-
TABLE 1
Abnormal blood tests in 1025 intra
Maternal blood tests %
abnormal (n tested) 9
Thrombocytes 100 x 103/L
...................................................................................................................














Gamma-glutamyl transferase 40 IU/L
...................................................................................................................






Free thyroxine 10.0 pmol/L 1
...................................................................................................................
Free thyroxine 24.0 pmol/L
...................................................................................................................
Random plasma glucose 6.1–11.0 mmol/L 1
...................................................................................................................
Random plasma glucose 11.1 mmol/L
...................................................................................................................












AC, anticardiolipin; CI, confidence interval; TSH, thyroid-stimu
a Free protein S2 but normal total protein S.
Korteweg. Fetal death workup. Am J Obstet Gynecol 2012known cause of death. r
53.e4 American Journal of Obstetrics& GynecologOf the women tested for toxoplas-
mosis, rubella, cytomegalovirus, herpes
implex virus (TORCH), parvovirus
19, syphilis, or hepatitis B surface-anti-
en, 17.9% (95% CI, 15.6–20.5) had
ositive IgM antibody titers to one of
hese infectious agents or a positive hep-
titis B surface-antigen (Table 2). In
.8% of the total cohort (n  1025) in-
rauterine infection was allocated as
ause of death, supported by placental or
utopsy findings. Of the 739 performed
etal ear/throat and 612 placental swabs,
espectively, 25.3% and 22.8%were pos-
tive for1microorganism (Table 2).Of
he positive fetal and placental swabs in,









(976) 0.9–2.7 Protein C
.........................................................................................................................
(1007) 1.5–3.5 Total protein S
.........................................................................................................................




(988) 78.0–83.0 Inherited thrombophilias
.........................................................................................................................












(902) 0.03–0.8 Lupus anticoagulant
.........................................................................................................................
(881) 17.2–22.5 Random homocystein
.........................................................................................................................














hormone; VWF, Von Willebrand factor.ichia coli or group B streptococcus was n
y JANUARY 2012etected. Of the examined placentas
n  1011) 12.7% (95% CI, 10.7–14.9)
howed histological chorioamnionitis
ithout funisitis and only 21.9% and
5.9% of the fetal and placental swabs in
hese cases were positive.
As is also shown in Table 2 abnormal
ndings were observed in 51.5% of per-
ormed autopsies, 89.2% of placentas,
0.6% ofMRI, and 7.3% of radiography.
bnormal autopsy or placental histolog-
cal evaluation were defined as abnormal
ndings stated in the conclusion of the
athology report performed by the
athologist. Minor abnormal findings
tated in the report concerning macro-




























1.5 (865) 0.8–2.6 3%
..................................................................................................................
2.9 (733) 1.8–4.4 5%
..................................................................................................................






















































.ot mentioned in the conclusion of the
www.AJOG.org Obstetrics Researchreport were not regarded as clinically rel-
evant. Cytogenetic analysis was per-
formed in 700 IUFDs (68.3%) and a suc-
cessful result was obtained in 362 deaths
(51.7%). The prevalence of a chromo-
somal abnormality in these 362 IUFDs
was 11.9% (95% CI, 8.7–15.7). Of these
43 chromosomal abnormalities, 37.2%
was trisomy 21, 23.3% trisomy 18, 16.3%
monosomy (45, X), 4.6% trisomy 13,
and in 18.6% other chromosomal ab-
normalities were found.
Adjudication of cause of death
The main causes of death in the total
TABLE 2
Abnormal viral serology tests, cultu
















Herpes simplex virus IgG 63.3
...................................................................................................................
Herpes simplex virus IgM 7.9
...................................................................................................................
Parvovirus B19 IgG 62.8
...................................................................................................................






























CI, confidence interval; MRI, magnetic resonance imaging; PC
Korteweg. Fetal death workup. Am J Obstet Gynecol 2012cohort of 1025 deaths were placental wpathology (65.2%), congenital anomaly
(4.8%), infection (1.8%), and other
(5.0%) while in 23.2% the cause re-
mained unknown. Subgroups of causes,
mechanism, and origin of mechanism of
death are presented in Table 3. Deaths
caused by fetal maternal hemorrhage
(FMH)of unknownoriginwith evidence
of fetal anemia confirmed by placental
examination and/or autopsy (1.3%) were
classified according to the Tulip classifi-
cation as caused by placental paren-
chyma pathology (n  10) or placenta
not otherwise specified (n  3), both
s, and other
deaths
mal (n tested) 95% CI
l Fetal
4) 20.8–26.3 9.8 (41) 2.7–23.1
..................................................................................................................
6) 0.7–2.3 0 (42) 0–8.4
..................................................................................................................
4) 88.4–92.3 75.7 (37) 58.8–88.2
..................................................................................................................
3) 2.1–4.6 0 (37) 0–9.5
..................................................................................................................
1) 43.5–50.0 42.5 (40) 27.0–59.1
..................................................................................................................
4) 1.4–3.4 0 (46) 0–7.7
..................................................................................................................
1) 59.8–66.6 50.0 (40) 33.8–66.2
..................................................................................................................
6) 6.1–9.9 0 (41) 0–8.6
..................................................................................................................
9) 59.5–66.1 45.0 (40) 29.3–61.5
..................................................................................................................
2) 1.3–3.3 2.3 (43) 0.06–12.3
..................................................................................................................


























lymerase chain reaction.ith origin of mechanism excessive
JANUARY 2012 Ameribleeding. In 10.6% of the total cohort
FMHwas observed as a contributing fac-
tor. Diabetes-related diseasewas cause of
death only twice in which maternal dia-
betic coma resulted in fetal death. In
4.0%of 1025 deaths diabetes-related dis-
ease was a contributing factor. Maternal
hyperthyroidism resulted in fetal death
only once; in 2.1% thyroid-related dis-
ease was a contributing factor. Most
deaths in the maternal disease group
“other” (1.3%) were caused by a known
antiphospholipid syndrome before the
index pregnancy (0.9%). The most fre-
quent observed maternal disease dur-
ing pregnancy was hypertension-re-
lated disease (15.1%); placental bed
pathology was in 65.8% the cause of
these deaths.
Value of diagnostics
After the evaluation of the contribu-
tion of each test for adjudication of
cause of death according to the Tulip
classification, the most valuable tests
were placental examination in 95.7%
(95% CI, 94.2–96.8), autopsy in 72.6%
(95% CI, 69.2–75.9), and cytogenetic
analysis in 29.0% (95% CI, 24.4–34.0)
(Table 4). The tests not mentioned in
Table 4 including coagulation tests and
radiography were respectively never or
only once allocated as valuable for ad-
judication of the cause.
On the basis of our findingswederived
the following flowchart for an optimal
workup of basic and selective diagnostics
to determine the cause of fetal death
(Figure 2).
COMMENT
A fetal death workup guideline helps in
elucidating the cause of fetal death but
also aims to prevent unnecessary inves-
tigations. There is no international gen-
erally accepted diagnostic guideline for
fetal death. This study primarily ad-
dressed the contribution of a uniform
extensive nonselective protocol of diag-
nostic tests for the adjudication of the
cause according to the Tulip classifica-
tion in 1025 fetal deaths. This resulted in
a proposal for a basic and additional



















































.cess of making explicit the complex




















Research Obstetrics www.AJOG.orgchain of events eventually leading to ad-
judication of an underlying cause of
death during our panelmeetings, we also
assessed risk factors and the clinical set-
ting in which fetal death occurred.7
In accordance with others,15-17 we can-
ot overemphasize the value of autopsy.
arlier studies also provided evidence that
fter IUFDroutinemacroscopicandhisto-
ogical examination of the placenta is a
ecessary complement to autopsy con-
rmingclinical and/orautopsyfindings.18-20
TABLE 3
Cause of death, mechanism and orig





Congenital anomaly: syndrome; monogenic
...................................................................................................................
Congenital anomaly: syndrome; other
...................................................................................................................
Congenital anomaly: central nervous system
...................................................................................................................
Congenital anomaly: heart and circulatory system
...................................................................................................................




Congenital anomaly: other; single organ
...................................................................................................................
Congenital anomaly: other; multiple organ
...................................................................................................................
Placenta: placental bed pathology
...................................................................................................................
Placenta: placental pathology; development
...................................................................................................................
Placenta: placental pathology; parenchyma
...................................................................................................................
Placenta: placental pathology; localization
...................................................................................................................
Placenta: umbilical cord complication
...................................................................................................................






Other: fetal hydrops of unknown origin
...................................................................................................................
Other: maternal disease; diabetus mellitus
...................................................................................................................
Other: maternal disease; hyperthyroidism
...................................................................................................................
Other: maternal disease; other
...................................................................................................................
Other: out of the ordinary
...................................................................................................................
Unknown: despite thorough investigation
...................................................................................................................




IUFD, intrauterine fetal death.
Korteweg. Fetal death workup. Am J Obstet Gynecol 2012Both tests provide information that is n
53.e6 American Journal of Obstetrics& Gynecologpertinent to nearly every potential cause
of fetal death and in themajority of cases
exclude causes if there are no signs. Fur-
ther selective diagnostic testing may fol-
low after pathology results and/or sus-
pect clinical characteristics.
Although an autopsy is optimal, ear-
lier studies have acknowledged the value
of MRI as an alternative,21 particularly
for cerebral pathology.22 Our low per-
ormance rate ofMRI (6.0%) is probably
ue to our high autopsy rate, clinicians
of mechanism in 1025 IUFDs accordin















.1 (1) 5.0 (1)
.........................................................................................................................








































(1025) 100 (4) 100 (20)
.........................................................................................................................ot being familiar with fetal MRI and
y JANUARY 2012navailability of MRI services. MRI was
djudicated as valuable in only 2 cases
nd radiography even less. This is prob-
bly associated with inexperience of
ost radiologistswith reviewingMRI af-
er fetal death.MRI is generally advised if
here is suspicion of cerebral congenital
nomalies and radiography if there is
uspicion of congenital anomalies and
oth in the absence of autopsy.23
We observed chromosomal abnor-









































(2) 100 (59) 100 (61)
..................................................................................................................



















































































www.AJOG.org Obstetrics Researchadjudication of the cause, cytogenetic
analysis was the third most valuable
test (29.0%) and is advised for all
IUFDs by invasive testing before labor.
If no parental consent for invasive test-
ing is given, an umbilical cord sample
postpartum was second best.10 Newer cy-
ogenetic techniques in which tissue cul-
ure is not required such as molecular
aryotypingbyarray-basedanalysis results
n a more precise evaluation of submicro-
copic cytogenetic imbalances and should
TABLE 3












































100 (268) 100 (42) 100 (147)
...................................................................................................................e considered when karyotyping fails. oFMH was attributed as cause if there
as evidence of fetal anemia confirmed
y placental examination and/or au-
opsy in 1.3%. Others reported 3% of
eaths caused by FMH.24 We observed
FMH however in 11.9% of tested
women, comparable to 8% reported in
stillbirths earlier.25 This 12% frequency
ay be an overestimate since many of
hese cases could have been related to a
onpathologic event. We would be in-
lined to advise investigation of FMH







































(4) 100 (7) 100 (14)
.........................................................................................................................nly in caseswith suspicion.However, to
JANUARY 2012 Amerireserve erythrocytes until after pathol-
gy results are available is technically im-
ossible. We therefore recommend in-
estigation of FMH in all fetal deaths
efore induction of labor, to exclude
MH caused by labor itself.
The most convincing proof of an in-
ectious cause of death is an autopsywith
vidence of organ involvement with an
rganism potentially able to cause still-
irth and/or histological placental exam-
nation with infectious findings.26 Cho-

























5.4 (2) 11.9 (12)
..................................................................................................................


























































......... .........rioamnionitis by itself (12.7%) should

















Research Obstetrics www.AJOG.orgnot be considered a cause of stillbirth.
TORCH serology and cultures are tradi-
tionally advised in the evaluation of still-
birth. In our study placental examina-
tion and autopsy were able to support an
intrauterine infection as cause in only
1.8% of all fetal deaths. This is supported
by others.16,27 More infections were re-
ported by Petersson et al,4 24% in fetal
eaths 22 weeks of gestation, most
ommonly group B streptococcus. Dif-
erences could be explained due to our
trict criteria7 and the lack of use of mo-
lecular diagnostic technology. Based on
our findings we no longer recommend
routine screening for infections. We ad-
vise obtaining and storing blood for ma-
ternal virus serology for all IUFDs. This
can be analyzed if there are pathological
infectious findings. If there is clinical
TABLE 4
Valuable tests in relation to determ
Value of dia
Diagnostic tests K
Cause of death, n Total E
Chromosomal defect; numerical 29
.............................................................................................................................




Placenta: placental bed pathology 322
.............................................................................................................................
Placenta: placental pathology; development 193
.............................................................................................................................
Placenta: placental pathology; parenchyma 29
.............................................................................................................................
Placenta: placental pathology; localization 1
.............................................................................................................................
Placenta: umbilical cord complication 58
.............................................................................................................................




Other: fetal hydrops of unknown origin 34
.............................................................................................................................
Other: maternal disease; diabetes mellitus 2
.............................................................................................................................
Other: maternal disease; hyperthyroidism 1
.............................................................................................................................
Other: maternal disease; other 13
.............................................................................................................................
Other: out of the ordinary 1
.............................................................................................................................
Unknown: despite thorough investigation 162
.............................................................................................................................










Diagnostics were adjudicated valuable if: establishing cause o
AB, antibodies; MRI, magnetic resonance imaging.
Korteweg. Fetal death workup. Am J Obstet Gynecol 2012suspicion of infection this should be an-
53.e8 American Journal of Obstetrics& Gynecologalyzed together with maternal, fetal, and
placental cultures. However, in parts of
the world with a high prevalence of in-
fectious causes such as syphilis and ma-
laria28 testing all deaths may well be
advisable.
We recently concluded after analysis
of 750 fetal deaths that, except for VWF,
acquired and inherited thrombophilic
defects were not associated with fetal
death. Although a group of women with
fetal death had lowered plasma levels of
acquired thrombophilic defects when
compared to healthy pregnant women,
these levels remained within the normal
ranges for nonpregnant women. These
data provided no evidence for routine
testing of inherited or acquired throm-
bophilic defects after fetal death.8 This
is confirmed by our data of 1025 eval-
tion of cause in 1025 intrauterine fe
stics
uer-Betke Glucose testing


































th, excluding cause of death or missing for determination of cauuated fetal deaths. Thrombophilia test-
y JANUARY 2012ing should be considered in women with
IUFD and a family history of hereditary
thrombophilia or a personal history of
venous thromboembolism, to prevent
further maternal thromboembolisms.29
Overall about 10% of fetal deaths are
associated with maternal disease.30 We
bserved hypertension and diabetes-re-
ated disease during pregnancy in, re-
pectively, 15.1% and 4.0% of the total
ohort. Diabetes-related and thyroid-re-
ated disease as cause of death were rare.
owever, an increased HbA1c was often
bserved illustrating the needs for fur-
her scientific investigation into unes-
ablished gestational diabetes. Testing
or maternal disease in asymptomatic
omen has been suggested bymany6; we
recommend testing selectively if there is
a suspect clinical history or suspect cur-
deaths
Hb electro-phoresis





























































f dea se ofrent pregnancy. In cases with fetal hy-
www.AJOG.org Obstetrics Researchdrops tests to prove red cell alloimmuni-
zation, parvovirus B19 serology and
hemoglobin electrophoresis are advised
to exclude other causes of death as these
were considered valuable in these cases.
Obtaining amniotic fluid, which is ad-
vised for all fetal deaths, may also pro-
vide opportunities for investigation into
metabolic disease.
The value of this nationwide study
with 50 participating hospitals lies in its
size and the approach in which fetal
death was evaluated: a case-by-case eval-
uation of 1025 IUFDs. For establishing
the cause of deathwe used the Tulip clas-
sification for perinatal mortality that
separates cause, mechanism, and risk
factors that are often mixed in other sys-
tems.31 Having strict criteria, the Tulip
classification system itself influenced our
TABLE 4
Valuable tests in relation to determ
Antibody screening Anticardiolipin AB





























...................................................................................................................adjudication of causes and judgment asto whether tests were valuable. Not all
possible tests are needed to classify cause
of death in the Tulip classification. The
distribution of causes of death obviously
also influences the contribution of diag-
nostic tests.
In general, the occurrence of diagnos-
tic test abnormalities in our study was
low. A comparison of abnormal test re-
sults in IUFD vs live born was neither
planned nor performed. Some abnormal
tests may also be relatively common in
live births and therefore it may be difficult
to judge their relevance when found in a
cohort of stillbirths. However in our pro-
cedure of classifying the cause, we consid-
ered all available information including
the clinical setting in addition to abnormal
test results and other diagnostics.
The clinical implications of our find-
tion of cause in 1025 intrauterine fe
Mother viral serology Mother sw































0.0 4.9 11.5 0.8
.........................................................................................................................ings are presented in a flowchart for di-
JANUARY 2012 Ameriagnostic workup to determine cause of
fetal death according to the Tulip classi-
fication (Figure 2). Autopsy, placental
examination and cytogenetic analysis are
the basis for diagnostic workup for all fe-
tal deaths. We recommend further indi-
vidualized sequential testing to avoid
unnecessary investigations and positive
test results that do not identify the cause
of stillbirth and bring on anxiety. Modi-
fications to the guideline, for example
testing of HbA1c, can be applied in view
of risk factor assessment, declined au-
topsy consent, endemic differences in
causes of fetal death, local preferences
and different cultures, technology, or fi-
nancial resources.
Participating hospitals
We thank 50 Dutch hospitals for partici-
deaths (continued)
Fetus swabs


























































......... .........pating in our national IUFD study: Albert









Research Obstetrics www.AJOG.orgSchweitzer Hospital, Dordrecht; Alysis
Zorggroep Zevenaar; Amphia Hospital,
Breda; Amstelveen Hospital; Antonius
Hospital, Sneek; Atrium Medical Center,
Heerlen; Bronovo Hospital, the Hague;
Bethesda Hospital, Hoogeveen; Deventer
ospitals; Diaconessenhuis, Utrecht; Eras-
usUniversityHospital Rotterdam; Flevo
ospital, Almere; Gelre Hospitals, Apel-
oorn; Gelre Hospitals, Zutphen; Groene
art Hospital, Gouda; Haga Hospital, the
ague; Isala Klinieken, Zwolle; Kennemer
asthuis, Haarlem; Lange Land Hospital,
TABLE 4
Valuable tests in relation to determ
Fetus viral serology Cytogenetic analysis





































53.e10 American Journal of Obstetrics& Gynecoloter,Leiden;MaaslandHospital,Sittard;Mar-
tini Hospital, Groningen; Meander Medical
Center, Amersfoort; Medical Center Alk-
maar;Medical Center Leeuwarden; Med-
ical Center Rijnmond Zuid, Rotterdam;
Medical Spectrum Twente, Enschede;
Medical Center Haaglanden, the Hague;
Nij Smellinghe, Drachten; Rivieren-
land Hospital, Tiel; Rijnland Hospi-
tal, Leiderdorp; Rode Kruis Hospital,
Beverwijk; Ruwaard van Putten Hospi-
tal, Spijkenisse; Sint Elisabeth Hospital,
Tilburg; Sint Franciscus Gasthuis, Rot-
tion of cause in 1025 intrauterine fe
Autopsy Placenta
Missed Established Excluded Missed Establishe
13 3 1 13
....................................................................................................................................
....................................................................................................................................
6 15 2 1 5
....................................................................................................................................
16 155 44 319
....................................................................................................................................
8 1 59 28 193
....................................................................................................................................




1 6 14 6 50
....................................................................................................................................
























13.1 72.6 55.9 95.7
.........................................................................................................................terdam; Sint Lucas Andreas Hospital,
gy JANUARY 2012Amsterdam; Scheperhospital, Emmen;
Slingeland Hospital, Doetinchem; Streek-
ziekenhuis Midden Twente, Hengelo;
Twee Steden Hospital, Tilburg; Univer-
sity Medical Center Groningen; Univer-
sity Medical Center Utrecht; University
Medical Center Sint Radboud, Nijme-
gen; VieCuri Medical Center Noord
Limburg, Venlo; Vlietland Hospital,
Vlaardingen; Vrije University Medical
Center, Amsterdam; Walcheren Hospital,
Vlissingen; Westfries Gasthuis, Hoorn;
Wilhelmina Hospital, Assen; Zaans
deaths (continued)
MRI

























































......... .........Medical Center, Zaandam. f
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Guideline flowchart for diagnostic workup to investigate cause of fetal death
 
 
Basic investigation for all intrauterine fetal death antepartum 
review previous obstetric history, current pregnancy, antenatal investigations,  
maternal and paternal family and personal history 
 
counsel parents on value autopsy, placental examination, and cytogenetic analysis 
 
before induction of labor perform invasive cytogenetic analysis (amniocentesis or chorionic villus biopsy) and 
preserve tissue for possible additional future tests  
test for fetal maternal hemorrhage 
collect and store serum for maternal virus serology; analyze selectively 
Basic investigation for all intrauterine fetal death postpartum 
external fetal examination preferably by expert: documentation of morphological (ab)normalities and photo’s 
register birthweight and trimmed placental weight 
if no informed consent for invasive cytogenetic analysis, sample umbilical cord for cytogenetic analysis 
 
placental examination including histopathology 
if antepartum/postpartum suspected cerebral congenital anomalies   MRI  
if antepartum/postpartum suspected congenital anomalies  radiography 
autopsy 
if no autopsy consent  discuss selective autopsy  
external fetal examination by expert familiar with congenital anomalies including photographs, MRI, and radiography 
Selective investigation intrauterine fetal death 
if clinical signs and symptoms of maternal disease: 
suspected hypertension-related disease  blood tests and test urine for albumen 
suspected disturbed thyroid function  thyroid-stimulating hormone, free thyroxine (T4) 
suspected diabetes-related disease, macrosomia (history), a strong family history of diabetes, or obesity  
glucose screening: such as glycated hemoglobin (HbA1c) or oral glucose tolerance test  
if suspected drug use  toxicology screen 
if signs of fetal hydrops  antibody screening, parvovirus B19 serology and hemoglobin electrophoresis, 
amniotic fluid testing for possible investigation into metabolic disease 
 
if clinical signs of infection: collect and analyze vaginal-rectal swab mother, fetal, and placental swabs  
and analyze maternal virus serology and amniotic fluid for molecular diagnostic technology 
if signs of infection in placenta or at autopsy  determine maternal viral serology and amniotic fluid for molecular 
diagnostic technology 
in women with a family history of hereditary thrombophilia or a personal history of venous thromboembolism  
perform thrombophilia work-up several months postpartum  
All IUFD: multidisciplinary panel classification meetings for evaluation cause of intrauterine fetal death  
IUFD, intrauterine fetal death; MRI, magnetic resonance imagine.
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